Telepathology and predictive algorithms will create growth opportunities, finds Frost & Sullivan
Santa Clara, Calif. – October 19, 2017 – The use of digital pathology has been largely restricted to research applications. While pathology laboratories have transitioned to digital workflows over the past 10 years, digitization and automation have penetrated only certain parts of the pathology workflow, leaving ample scope for deploying a complete, fully digitized, end-to-end automated workflow. The United States Food and Drug Administration’s (FDA) recent de novo clearance of Philip’s IntelliSite platform is paving the way for wider clinical applications of the technology.
“User perception that whole slide imaging will always be inferior to the light microscope has traditionally limited digital pathology to research, teaching/education, and clinical diagnosis applications. Stringent regulatory pathways and the differing time, productivity and quality requirements in clinical environment further compound barriers,” explained Transformational Health Principal Analyst Divyaa Ravishankar. “Nevertheless, innovations centered on cloud hosting and image analysis will increase adoption among future users and also generate merger and acquisition opportunities for vendors.” Leading market players are Roche Diagnostics (Ventana), Leica Biosystems, Cerner, Philips, Sunquest, 3DHistech, Proscia, Inspirata, Indica Labs, Definiens, and Visiopharm.
2017 Customer Attitudes and Adoption Plans of Digital Pathology Technologies is part of Frost & Sullivan’s Life Sciences Growth Partnership Service program. The study is based on an extensive survey of substantial users—pathologists and lab managers that influence purchase decisions—of digital pathology equipment. Of the 253 candidates attempted the survey and 154 candidates qualified for the survey.
To access more information on this analysis, please visit: https://frost.ly/1vf
The primary goal of this research is to identify trends and developments in the field of digital pathology. The survey seeks to collect the main information and compare the perceptions of current and potential adopters of this technology. In addition, it analyzes the intended use case, adoption of cloud pathology, barriers to adoption, budgets and the brand perception (Scanners, image analysis, archiving, PACS and APLIS solutions). Moreover, it describes the image storage, format, size and monthly storage requirements. Several notable insightsemerged from the survey:
- Despite the recent FDA clearance of the digital pathology platform, respondents indicated that it will not have a major impact on the uptake of the technology or extension of the technology to clinical application.
- There is a high inclination toward cloud-enabled solutions among current and future users with very few citing privacy and institutional restrictions.
- Automated image analysis will be an important driver for adoption of digital pathology amidst current and future users; respondents preferred image analysis modules sold through slide scanner providers as opposed to outsourcing to third-party providers.
- Frequently outsourced areas were cloud hosting, workflow management such as image analysis slide scanning, and telepathology.
The top reasons cited by both molecular pathology and histopathology users for not investing earlier in digital pathology solutions were high cost of the technology, insufficient workload, laboratory information system (LIS) connectivity, and lack of digitization of the workflow. The majority of future buyers (28.1 percent) had annual lab budgets allocated for <$50,000 with more money to spare for new equipment purchase in the $100,000-$250,000 category. The survey also revealed that future planned purchases might still revolve around slide scanning hardware and microscopes with digital imaging capabilities, followed by LIS, storage hardware, and virtual image analysis tools.
“The lack of adequate budgets from the potential adopter community should be an eye-opener for vendors to devise targeted pricing strategies for their instruments and software,” noted Ravishankar. “In addition to price, major vendor selection criteria among future adopters were ease of operation, customer support and training, image quality and color fidelity, and existing satisfactory relationship.”
2017 Customer Attitudes and Adoption Plans of Digital Pathology Technologies is part of Frost & Sullivan’s Life Sciences Growth Partnership Service program.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion
2017 Customer Attitudes and Adoption Plans of Digital Pathology Technologies
K20A
Contact:
Mariana Fernandez
Corporate Communications – North America
P: +1 (210) 348 1012
E: Mariana.Fernandez@frost.com
Twitter: @FS_Healthcare
LinkedIn: Transform Health
